Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CAPRNASDAQ:PEPGNASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCAPRCapricor Therapeutics$13.23+3.4%$14.23$3.52▼$23.40$601.57M4.11.36 million shs696,830 shsPEPGPepGen$2.39+6.2%$2.07$1.16▼$19.30$78.13M0.96788,883 shs229,186 shsSRPTSarepta Therapeutics$97.19-1.2%$111.73$97.06▼$173.25$9.43B0.79916,983 shs874,067 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCAPRCapricor Therapeutics-2.14%-5.89%-5.12%-3.54%+115.32%PEPGPepGen-8.91%-7.02%+82.93%-51.92%-83.64%SRPTSarepta Therapeutics-1.40%-6.81%-10.31%-20.48%-19.34%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCAPRCapricor Therapeutics1.9749 of 5 stars3.51.00.00.03.00.80.6PEPGPepGen2.5502 of 5 stars3.22.00.00.02.91.71.3SRPTSarepta Therapeutics4.7742 of 5 stars4.41.00.04.23.82.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCAPRCapricor Therapeutics 3.00Buy$34.50160.77% UpsidePEPGPepGen 2.33Hold$10.33332.36% UpsideSRPTSarepta Therapeutics 2.83Moderate Buy$170.4175.34% UpsideCurrent Analyst Ratings BreakdownLatest CAPR, SRPT, and PEPG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/7/2025SRPTSarepta TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Perform$105.003/4/2025CAPRCapricor TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$77.00 ➝ $77.002/27/2025SRPTSarepta TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$165.00 ➝ $161.002/27/2025SRPTSarepta TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$202.00 ➝ $202.002/27/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell ➝ Sell$75.00 ➝ $75.002/24/2025PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.002/13/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell ➝ Sell$75.00 ➝ $75.002/11/2025SRPTSarepta TherapeuticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold$136.001/30/2025PEPGPepGenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $16.001/30/2025SRPTSarepta TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell ➝ Sell$75.00 ➝ $75.001/27/2025SRPTSarepta TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$202.00 ➝ $202.00(Data available from 3/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCAPRCapricor Therapeutics$23.23M25.90N/AN/A$0.73 per share18.12PEPGPepGenN/AN/AN/AN/A$4.55 per shareN/ASRPTSarepta Therapeutics$1.90B4.96N/AN/A$9.19 per share10.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCAPRCapricor Therapeutics-$22.29M-$1.06N/AN/AN/A-146.86%-112.95%-57.00%3/19/2025 (Estimated)PEPGPepGen-$78.63M-$2.84N/AN/AN/AN/A-60.17%-48.88%5/13/2025 (Estimated)SRPTSarepta Therapeutics-$535.98M$2.2877.758.88N/A7.43%11.00%3.35%5/7/2025 (Estimated)Latest CAPR, SRPT, and PEPG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/19/2025N/ACAPRCapricor Therapeutics-$0.31N/AN/AN/A$9.87 millionN/A2/24/2025Q4 2024PEPGPepGen-$0.81-$0.68+$0.13-$0.68N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCAPRCapricor TherapeuticsN/AN/AN/AN/AN/APEPGPepGenN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCAPRCapricor TherapeuticsN/A4.194.19PEPGPepGenN/A8.478.47SRPTSarepta Therapeutics0.933.843.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCAPRCapricor Therapeutics21.68%PEPGPepGen58.01%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipCAPRCapricor Therapeutics12.00%PEPGPepGen4.60%SRPTSarepta Therapeutics7.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCAPRCapricor TherapeuticsN/A45.47 million40.01 millionOptionablePEPGPepGen3032.69 million31.10 millionNot OptionableSRPTSarepta Therapeutics1,31497.03 million88.17 millionOptionableCAPR, SRPT, and PEPG HeadlinesRecent News About These CompaniesInsider Selling: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Director Sells 2,491 Shares of StockMarch 14 at 6:54 AM | insidertrades.comConnor Clark & Lunn Investment Management Ltd. Raises Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)March 14 at 4:54 AM | marketbeat.comVictory Capital Management Inc. Grows Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)March 14 at 3:30 AM | marketbeat.comErste Asset Management GmbH Raises Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)March 13 at 5:58 AM | marketbeat.comUS Bancorp DE Sells 2,803 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)March 13 at 3:13 AM | marketbeat.comRBC Capital Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)March 12 at 11:00 AM | markets.businessinsider.comSPX Gestao de Recursos Ltda Invests $1.22 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)March 11 at 6:13 AM | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Hits New 12-Month Low - What's Next?March 11 at 4:47 AM | marketbeat.comCharles Schwab Investment Management Inc. Acquires 12,000 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)March 11 at 3:36 AM | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Research Coverage Started at ScotiabankMarch 10, 2025 | americanbankingnews.comAssetmark Inc. Purchases 3,734 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)March 9, 2025 | marketbeat.comScotiabank Initiates Coverage of Sarepta Therapeutics (SRPT) with Sector Perform RecommendationMarch 8, 2025 | msn.comSarepta Therapeutics (NASDAQ:SRPT) Now Covered by ScotiabankMarch 8, 2025 | marketbeat.comA Closer Look At Sarepta Therapeutics' EarningsMarch 7, 2025 | finance.yahoo.comInceptionr LLC Makes New Investment in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)March 7, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Hits New 52-Week Low - Time to Sell?March 6, 2025 | marketbeat.comProficio Capital Partners LLC Invests $3.83 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)March 5, 2025 | marketbeat.comSpotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4March 4, 2025 | msn.comSarepta Therapeutics' Long-Term Potential Intact Despite Near-Term Stock WeaknessMarch 4, 2025 | seekingalpha.comSarepta files automatic mixed securities shelfMarch 3, 2025 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Sarepta Therapeutics (SRPT), Schrodinger (SDGR)March 3, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCAPR, SRPT, and PEPG Company DescriptionsCapricor Therapeutics NASDAQ:CAPR$13.23 +0.44 (+3.44%) Closing price 04:00 PM EasternExtended Trading$13.35 +0.12 (+0.91%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. PepGen NASDAQ:PEPG$2.39 +0.14 (+6.22%) Closing price 04:00 PM EasternExtended Trading$2.35 -0.04 (-1.72%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.Sarepta Therapeutics NASDAQ:SRPT$97.19 -1.18 (-1.20%) Closing price 04:00 PM EasternExtended Trading$97.29 +0.10 (+0.10%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead How Super Micro Computer Stock Is Defying the Market Sell-Off Palantir’s Deal With Archer Aviation Keeps AI’s Future in Focus D-Wave Quantum Stock Jumps on "Quantum Supremacy" News Is a Bottom Finally Forming in Rocket Lab Stock? Intel Stock Surges on New CEO – The Real Story Runs Deeper AMD Stock: Can the PC Refresh Cycle Spark a Rally? Ramaco Resources Pins Hopes on Coal's Untapped Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
